Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer’s disease: review and current status

Author： Gottwald M.D.   Rozanski R.I.  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.8, Iss.10, 1999-10, pp. : 1673-1682

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer’s disease

By Cummings J.L.   Ringman J.M.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 4, 1999-04 ,pp. : 463-471

Informa Healthcare

Access to resources Recommend Favorite

Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson’s disease: review and current status

By Gottwald M.D.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 4, 1999-04 ,pp. : 453-462

Informa Healthcare

Access to resources Recommend Favorite

Review of rivastigmine and its clinical applications in Alzheimer’s disease and related disorders

By Desai A.   Grossberg G.  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 4, 2001-04 ,pp. : 653-666

Informa Healthcare

Access to resources Recommend Favorite

Rivastigmine: A Pharmacoeconomic Review of its Use in Alzheimer’s Disease

By Lamb H.M.   Goa K.L.  

PharmacoEconomics, Vol. 19, Iss. 3, 2001-03 ,pp. : 303-318

Adis International

Access to resources Recommend Favorite

Chemical synthesis of galantamine, an acetylcholinesterase inhibitor for treatment of Alzheimer’s disease

By Marco-Contelles José   Rodríguez Carolina   García Antonio G  

Expert Opinion on Therapeutic Patents, Vol. 15, Iss. 5, 2005-05 ,pp. : 575-587

Informa Healthcare

Access to resources Recommend Favorite